Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular
edema secondary to retinal vein occlusion in patients that have previously failed treatment
with other macular edema treatments including bevacizumab.